These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 21987240)

  • 41. Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimens.
    Stewart WC; Crean CS; Zink RC; Brubaker K; Haque RM; Hwang DG
    Am J Ophthalmol; 2010 Nov; 150(5):744-751.e2. PubMed ID: 20813346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacokinetics and tissue residues of moxifloxacin in broiler chickens.
    Goudah A
    Br Poult Sci; 2009 Mar; 50(2):251-8. PubMed ID: 19373726
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
    Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
    J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Superior calcium bioavailability of effervescent potassium calcium citrate over tablet formulation of calcium citrate after Roux-en-Y gastric bypass.
    Sakhaee K; Pak C
    Surg Obes Relat Dis; 2013; 9(5):743-8. PubMed ID: 22222299
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Hariprasad SM; Shah GK; Mieler WF; Feiner L; Blinder KJ; Holekamp NM; Gao H; Prince RA
    Arch Ophthalmol; 2006 Feb; 124(2):178-82. PubMed ID: 16476886
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of sucralfate on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers.
    Stass H; Schühly U; Möller JG; Delesen H
    Clin Pharmacokinet; 2001; 40 Suppl 1():49-55. PubMed ID: 11352442
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man.
    Stass H; Kubitza D
    J Antimicrob Chemother; 1999 May; 43 Suppl B():83-90. PubMed ID: 10382880
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Vitreal penetration of oral and topical moxifloxacin in humans.
    Fuller JJ; Lott MN; Henson NM; Bhatti AA; Singh H; McGwin G; Marcus DM
    Am J Ophthalmol; 2007 Feb; 143(2):338-40. PubMed ID: 17258525
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Vitreous and aqueous penetration of orally administered moxifloxacin in humans.
    Vedantham V; Lalitha P; Velpandian T; Ghose S; Mahalakshmi R; Ramasamy K
    Eye (Lond); 2006 Nov; 20(11):1273-8. PubMed ID: 16200061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers.
    Boonleang J; Panrat K; Tantana C; Krittathanmakul S; Jintapakorn W
    Clin Ther; 2007 Apr; 29(4):703-10. PubMed ID: 17617293
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis.
    Nijland HM; Ruslami R; Suroto AJ; Burger DM; Alisjahbana B; van Crevel R; Aarnoutse RE
    Clin Infect Dis; 2007 Oct; 45(8):1001-7. PubMed ID: 17879915
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absolute bioavailability of intranasal fluticasone furoate in healthy subjects.
    Allen A; Down G; Newland A; Reynard K; Rousell V; Salmon E; Scott R
    Clin Ther; 2007 Jul; 29(7):1415-20. PubMed ID: 17825692
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relative bioavailability and pharmacokinetic properties of two different enteric formulations of esomeprazole in healthy Bangladeshi male volunteers: An open-label, single-dose, randomized-sequence, two-way crossover study.
    Ullah MA; Shams-Ud-Dowla ; Maruf AA; Azad MA; Shohag MH; Sultana R; Latif AH; Hasnat A
    Clin Ther; 2010 Jul; 32(7):1419-26. PubMed ID: 20678688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Determination of aqueous and vitreous concentration of moxifloxacin 0.5% after delivery via a dissolvable corneal collagen shield device.
    Hariprasad SM; Shah GK; Chi J; Prince RA
    J Cataract Refract Surg; 2005 Nov; 31(11):2142-6. PubMed ID: 16412929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bioavailability and bioequivalence of two oral formulations of alendronate sodium 70 mg: an open-label, randomized, two-period crossover comparison in healthy Korean adult male volunteers.
    Rhim SY; Park JH; Park YS; Lee MH; Kim DS; Shaw LM; Yang SC; Kang JS
    Clin Ther; 2009 May; 31(5):1037-45. PubMed ID: 19539104
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of 2 moxifloxacin regimens for preoperative prophylaxis: prospective randomized triple-masked trial. Part 1: aqueous concentration of moxifloxacin.
    Vasavada AR; Gajjar D; Raj SM; Vasavada V; Vasavada V
    J Cataract Refract Surg; 2008 Aug; 34(8):1379-82. PubMed ID: 18655991
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of cataract surgery on ocular levels of topical moxifloxacin.
    Mather R; Stewart JM; Prabriputaloong T; Wong J; McLeod SD
    Am J Ophthalmol; 2004 Oct; 138(4):554-9. PubMed ID: 15488780
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of moxifloxacin in critically ill patients with impaired renal function undergoing pulse high-volume haemofiltration.
    Zhang L; Li L; Shi W; Liu S; Liang X; Ye Z; Wang WJ; Zhang B; Li R; Chen Y; Yu C; Zhuo L; Wang X
    Int J Antimicrob Agents; 2013 Sep; 42(3):244-9. PubMed ID: 23876335
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Relative bioavailability of sapropterin from intact and dissolved sapropterin dihydrochloride tablets and the effects of food: a randomized, open-label, crossover study in healthy adults.
    Musson DG; Kramer WG; Foehr ED; Bieberdorf FA; Hornfeldt CS; Kim SS; Dorenbaum A
    Clin Ther; 2010 Feb; 32(2):338-46. PubMed ID: 20206791
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of iron supplements on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in humans.
    Stass H; Kubitza D
    Clin Pharmacokinet; 2001; 40 Suppl 1():57-62. PubMed ID: 11352443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.